Your browser is no longer supported. Please, upgrade your browser.
Settings
ILMN Illumina, Inc. daily Stock Chart
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E57.65 EPS (ttm)3.13 Insider Own0.70% Shs Outstand147.02M Perf Week3.31%
Market Cap26.49B Forward P/E41.71 EPS next Y4.32 Insider Trans-3.00% Shs Float144.73M Perf Month7.46%
Income462.60M PEG4.65 EPS next Q0.64 Inst Own95.20% Short Float3.37% Perf Quarter12.00%
Sales2.40B P/S11.05 EPS this Y0.90% Inst Trans0.10% Short Ratio5.25 Perf Half Y26.16%
Book/sh14.97 P/B12.04 EPS next Y18.52% ROA11.40% Target Price163.81 Perf Year25.50%
Cash/sh10.60 P/C17.00 EPS next 5Y12.39% ROE21.80% 52W Range119.37 - 186.88 Perf YTD40.74%
Dividend- P/FCF63.72 EPS past 5Y38.00% ROI14.00% 52W High-3.57% Beta0.76
Dividend %- Quick Ratio2.90 Sales past 5Y17.80% Gross Margin69.50% 52W Low50.96% ATR3.90
Employees5500 Current Ratio3.30 Sales Q/Q4.70% Oper. Margin24.50% RSI (14)67.14 Volatility2.07% 2.13%
OptionableYes Debt/Eq0.48 EPS Q/Q19.20% Profit Margin19.30% Rel Volume0.88 Prev Close175.29
ShortableYes LT Debt/Eq0.48 EarningsApr 25 AMC Payout0.00% Avg Volume928.21K Price180.20
Recom2.60 SMA204.33% SMA507.39% SMA20015.14% Volume820,454 Change2.80%
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Jan-06-17Upgrade CL King Neutral → Buy
Dec-07-16Reiterated Morgan Stanley Underweight $115 → $100
Nov-10-16Resumed Leerink Partners Mkt Perform
Nov-02-16Downgrade First Analysis Sec Equal-Weight → Underweight $130 → $116
Oct-11-16Reiterated Cantor Fitzgerald Hold $165 → $155
Oct-11-16Reiterated Canaccord Genuity Hold $165 → $136
Oct-11-16Downgrade Citigroup Buy → Neutral
Aug-22-16Downgrade CL King Buy → Neutral
Jul-27-16Reiterated Mizuho Neutral $138 → $148
Jul-05-16Downgrade Morgan Stanley Equal-Weight → Underweight $130 → $110
Jun-22-16Initiated CL King Buy
May-04-16Reiterated Stifel Buy $215 → $160
May-04-16Reiterated Mizuho Neutral $150 → $138
May-04-16Reiterated Canaccord Genuity Hold $160 → $140
May-03-16Reiterated UBS Buy $210 → $180
May-03-16Reiterated Morgan Stanley Overweight $140 → $130
Apr-24-17 04:47PM  Top Stocks In Buy Zone Ahead Of Results: Investing Action Plan Investor's Business Daily
Apr-22-17 06:43AM  3 Things to Look for in Illumina's Q1 Results Motley Fool
Apr-21-17 08:51AM  Should You Sell llumina (ILMN) Before Earnings? Zacks
Apr-20-17 04:20PM  The Top Gene-Sequencing Stock to Buy in 2017 Motley Fool
Apr-17-17 09:32AM  Can Illumina (ILMN) Spring a Surprise this Earnings Season? Zacks
09:30AM  The Zacks Analyst Blog Highlights: Microsoft, BlackRock, Northrop Grumman, NVIDIA and Illumina Zacks
Apr-16-17 02:02PM  3 Big Reasons to Be Bullish on Biotech Stocks Motley Fool
Apr-13-17 02:49PM  Top Research Reports for Today: MSFT, BLK, NOC Zacks
08:58AM  Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe Zacks
Apr-12-17 08:47AM  The Long Game In Life Sciences: $181B Fund Baillie Gifford Invests Big In Private Companies Forbes
Apr-11-17 06:30AM  Illumina to Announce First Quarter 2017 Financial Results on Tuesday, April 25, 2017 Business Wire
Apr-10-17 02:00AM  Illumina Launches the VeriSeq NIPT Solution in Europe Business Wire
Apr-05-17 08:03AM  Better Buy: Illumina Inc. vs. Roche Holding AG Motley Fool
08:03AM  Better Buy: Illumina Inc. vs. Roche Holding AG
Apr-04-17 08:29AM  Apple's Streaming Aspirations Not Enough to Get by Facebook: Challenge Update TheStreet.com
08:29AM  Apple's Streaming Aspirations Not Enough to Get by Facebook: Challenge Update
Apr-03-17 04:57PM  Apple's Premium Streaming Aspirations Not Enough to Get by Facebook: Challenge Update
09:00AM  Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC Business Wire
Apr-02-17 05:20PM  Apple Walks All Over Nike, Facebook and Illumina Square Off: Challenge Update TheStreet.com
05:20PM  Apple Walks All Over Nike, Facebook and Illumina Square Off: Challenge Update
Apr-01-17 11:04AM  In Your 40s? 3 Stocks You Might Want to Buy Motley Fool
11:04AM  In Your 40s? 3 Stocks You Might Want to Buy at Motley Fool
Mar-31-17 08:30PM  Here Are Some of the Top Health Care Stocks in the First Quarter TheStreet.com
08:30PM  Here Are Some of the Top Health Care Stocks in the First Quarter
11:52AM  Innovation ETF (ARKK) Hits New 52-Week High
Mar-30-17 03:37PM  Nike, Apple, Illumina and Facebook Take Last 4 Spots in TheStreet's Market Bracket Challenge TheStreet.com
03:37PM  Nike, Apple, Illumina and Facebook Take Last 4 Spots in TheStreet's Market Bracket Challenge at TheStreet
10:46AM  Facebook Squanders Snap's Title Hopes, Nike Advances: Challenge Update TheStreet.com
10:46AM  Facebook Squanders Snap's Title Hopes, Nike Advances: Challenge Update
Mar-28-17 09:00AM  Macrogen Leads Precision Medicine by Advancing the Realization of the "$100 Genome Age" Business Wire
Mar-21-17 03:42PM  Here's Why the Best Is Yet to Come for Illumina, Inc. Motley Fool
03:42PM  Here's Why the Best Is Yet to Come for Illumina, Inc. at Motley Fool
Mar-20-17 01:37PM  Heres What Analysts Had To Say About Sonic, Alphabet, Illumina, FireEye, and Shake Shack at Insider Monkey
06:45AM  Illumina upgraded by Leerink Partners
Mar-19-17 11:01AM  Is Trump Bad for Healthcare Stocks? These 4 Winners Don't Think So at Motley Fool
Mar-17-17 09:58AM  Why We're Excited About These 3 Top Stocks at Motley Fool
08:17AM  Illumina, Inc. breached its 50 day moving average in a Bearish Manner : ILMN-US : March 17, 2017
07:39AM  Why Did the Healthcare Sector Fall on March 16?
Mar-16-17 03:12PM  Stock market pares post-Fed bounce as health care, utilities slump at MarketWatch
Mar-14-17 03:02PM  How You Can Profit From the Next Big Thing in Healthcare at Motley Fool
Mar-13-17 10:57AM  17 Year CIO Veteran Learns New Tricks As Illumina's CIO at Forbes
Mar-12-17 03:02PM  3 Huge Healthcare Trends and How to Invest in Them (Hint: One Is Marijuana) at Motley Fool
Mar-09-17 06:31PM  5 Stocks With Promising, Amazon-like Growth Potential at Motley Fool
Mar-08-17 09:24AM  1 Huge Reason to Buy Illumina, Inc. Stock Now at Motley Fool
03:52AM  CORRECTING and REPLACING Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma Business Wire
Mar-07-17 06:18PM  Opko Health subsidiary launches prenatal testing tool at bizjournals.com
12:11PM  Drug innovators will continue to do well: Isaly
08:21AM  What Illumina's and Bristol-Myers Squibb's Latest GRAIL Moves Mean for Investors at Motley Fool
08:00AM  OPKO Subsidiary GenPath Womens Health Announces the Availability of ClariTest GlobeNewswire
Mar-01-17 08:06AM  ILLUMINA INC Files SEC form 8-K, Other Events
Feb-28-17 09:30AM  OPKO Healths GeneDx Announces Participation in Illuminas iHope Program on International Rare Disease Day GlobeNewswire
09:00AM  Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program Business Wire
08:01AM  3 Top Healthcare Stocks to Buy Now at Motley Fool
06:00AM  Is Illumina On The Verge of a Breakout?
Feb-27-17 08:38PM  [$$] Medical Megadeals Dominate Deal Flow at The Wall Street Journal
05:08PM  The Hot Stock: Illumina Jumps 4.3% at Barrons.com
Feb-24-17 10:00AM  4 Stocks You Can Buy and Hold Forever at Motley Fool
Feb-21-17 01:21PM  ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers
11:57AM  Baron Opportunity Fund Comments on Illumina
06:30AM  Illumina to Webcast Live Presentation at the Cowen and Company Annual Health Care Conference Business Wire
Feb-20-17 09:00AM  Illumina Names John W. Thompson to Its Board of Directors, Bringing More Than 40 Years of Technology Leadership to Illumina Business Wire
Feb-18-17 08:45AM  Why Illumina Is a Buy at Motley Fool
Feb-17-17 11:27PM  Top Stocks Poised to Bounce Back in 2017 at Motley Fool
01:04PM  ILLUMINA INC Financials
Feb-15-17 08:20AM  3 Stocks Set to Profit From the Rise of China at Motley Fool
Feb-14-17 07:29AM  What Illumina's New Products Mean for 2017 and Beyond at Motley Fool
06:10AM  ILLUMINA INC Files SEC form 10-K, Annual Report
03:59AM  Better Buy: Illumina or Gilead Sciences? at Motley Fool
Feb-13-17 08:03PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses Exceeding $250,000 to Contact the Firm Accesswire
02:12PM  DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017 ILMN GlobeNewswire
12:43PM  Baron Funds' Fifth Avenue Growth Fund Comments on Illumina
12:30PM  IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses Exceeding $250,000 to Contact the Firm Accesswire
12:29PM  Baron Funds' Baron Fifth Avenue Growth Fund 4th Quarter Commentary
10:39AM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:10AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Illumina Inc. (ILMN) & Lead Plaintiff Deadline: February 14, 2017 GlobeNewswire
08:33AM  ILLUMINA INC Files SEC form 8-K, Other Events
Feb-08-17 04:53PM  Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific at Motley Fool
04:32PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
01:20PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017 ILMN Business Wire
Feb-07-17 02:22PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Illumina, Inc. - ILMN PR Newswire
12:40PM  IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:40AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Illumina Inc. (ILMN) and Lead Plaintiff Deadline: February 14, 2017 Accesswire
Feb-06-17 04:21PM  Why Illumina, Inc. Soared 25% in January at Motley Fool
11:36AM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
07:16AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Illumina, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline Accesswire
Feb-04-17 07:22AM  5 Best Stocks for High-Risk Investors at Motley Fool
Feb-03-17 08:51PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
08:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Illumina, Inc. of Class Action Lawsuit and Upcoming Deadline - ILMN Accesswire
12:54PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:39AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Illumina Inc. (ILMN) and Lead Plaintiff Deadline: February 14, 2017 Accesswire
10:04AM  ILMN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Illumina, Inc. and a Lead Plaintiff Deadline of February 14, 2017 Business Wire
Feb-02-17 10:43AM  Illumina, Inc. :ILMN-US: Earnings Analysis: 2016 By the Numbers : February 2, 2017
09:21AM  Illumina, Inc. :ILMN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 2, 2017
06:51AM  [$$] Illumina, Up 26% So Far This Year, Can Stay Hot at Barrons.com
06:45AM  5 Things Illumina's Management Wants You to Know at Motley Fool
Feb-01-17 03:43PM  Illumina Q4 Results Beat the Street at Investopedia
12:30PM  Pacific Biosciences: A Small Cap Gem in the Genomics Market at Motley Fool
12:06PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:30AM  Investor Alert: GPM Reminds Investors of the February 14 Deadline in the Class Action Lawsuit Against Illumina, Inc. Business Wire
08:14AM  Top Healthcare Stocks to Buy in 2017 at Motley Fool
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina's BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOWMAN A BLAINEDirectorApr 12Option Exercise75.663,000226,98018,704Apr 13 06:40 PM
BOWMAN A BLAINEDirectorApr 12Sale172.723,000518,15115,704Apr 13 06:40 PM
BRADBURY DANIELDirectorApr 07Option Exercise71.0960042,65417,065Apr 11 08:16 PM
BRADBURY DANIELDirectorApr 07Sale172.79600103,67516,465Apr 11 08:16 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 24Sale170.001,672284,24029,586Mar 28 07:05 PM
BRADBURY DANIELDirectorMar 21Option Exercise71.0960042,65417,065Mar 23 02:14 PM
BRADBURY DANIELDirectorMar 21Sale163.5660098,13416,465Mar 23 02:14 PM
BOWMAN A BLAINEDirectorMar 08Option Exercise75.663,000226,98018,704Mar 10 07:41 PM
BOWMAN A BLAINEDirectorMar 08Sale164.883,000494,63315,704Mar 10 07:41 PM
BRADBURY DANIELDirectorFeb 17Option Exercise71.0960042,65417,065Feb 21 09:05 PM
BRADBURY DANIELDirectorFeb 17Sale162.8060097,67716,465Feb 21 09:05 PM
Bouchard MichelChief Accounting OfficerFeb 15Option Exercise0.002,625025,292Feb 17 08:11 PM
deSouza Francis APresident and CEOFeb 15Option Exercise0.0014,318082,523Feb 17 09:05 PM
Stapley MarcEVP & Chief Administrative OfcFeb 15Option Exercise0.008,438044,423Feb 17 08:51 PM
Ronaghi MostafaSr VP & CTOFeb 15Option Exercise0.007,032067,922Feb 17 08:45 PM
FLATLEY JAY TDirectorFeb 15Option Exercise0.0028,5100527,236Feb 17 08:37 PM
Dadswell CharlesSr VP & General CounselFeb 15Option Exercise0.007,032014,699Feb 17 08:22 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 15Option Exercise0.008,438033,009Feb 17 08:16 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 13Sale163.102,173354,41624,571Feb 15 07:42 PM
BOWMAN A BLAINEDirectorFeb 08Option Exercise70.193,000210,56018,704Feb 10 03:55 PM
BOWMAN A BLAINEDirectorFeb 08Sale162.743,000488,23115,704Feb 10 03:55 PM
Dadswell CharlesSr VP & General CounselFeb 06Sale161.2657292,2417,592Feb 08 07:39 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 02Sale160.411,104177,09326,586Feb 06 08:17 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 30Sale160.9025941,67327,690Jan 31 07:31 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 19Sale160.3537860,61228,662Jan 19 05:56 PM
OSTADAN OMEADEVP Ops, Products, StrategyJan 17Sale160.002,000320,00029,040Jan 19 05:56 PM
BOWMAN A BLAINEDirectorJan 11Option Exercise42.823,000128,46018,704Jan 13 07:05 PM
BOWMAN A BLAINEDirectorJan 11Sale162.893,000488,65815,704Jan 13 07:05 PM
Dadswell CharlesSr VP & General CounselJan 10Sale161.6011618,7468,420Jan 12 09:36 PM
BRADBURY DANIELDirectorJan 04Option Exercise71.0960042,65417,065Jan 06 06:59 PM
BRADBURY DANIELDirectorJan 04Sale135.0160081,00816,465Jan 06 06:59 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 15Sale126.162,000252,32031,040Dec 19 08:08 PM
BRADBURY DANIELDirectorDec 12Option Exercise71.0960042,65417,065Dec 14 08:09 PM
BRADBURY DANIELDirectorDec 12Sale123.4260074,05416,465Dec 14 08:09 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 08Sale121.633,000364,89052,988Dec 09 04:18 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Sale133.303,000399,90051,492Dec 05 06:41 PM
BRADBURY DANIELDirectorNov 14Option Exercise71.0960042,65417,065Nov 15 06:14 PM
BRADBURY DANIELDirectorNov 14Sale136.3460081,80316,465Nov 15 06:14 PM
BRADBURY DANIELDirectorOct 07Option Exercise71.0960042,65417,065Oct 11 08:35 PM
BRADBURY DANIELDirectorOct 07Sale184.36600110,61316,465Oct 11 08:35 PM
Dadswell CharlesSr VP & General CounselOct 04Sale182.3811621,15639,900Oct 06 05:32 PM
EPSTEIN ROBERT SDirectorSep 20Sale174.2930052,2876,924Sep 21 06:56 PM
Stapley MarcEVP & Chief Administrative OfcSep 15Sale172.871,270219,54332,746Sep 16 08:07 PM
BRADBURY DANIELDirectorSep 14Option Exercise71.0960042,65417,065Sep 16 07:58 PM
BRADBURY DANIELDirectorSep 14Sale171.25600102,74816,465Sep 16 07:58 PM
Dadswell CharlesSr VP & General CounselSep 06Sale168.0111619,48940,016Sep 08 07:58 PM
FLATLEY JAY TDirectorAug 23Option Exercise36.3020,000726,000508,061Aug 25 08:43 PM
FLATLEY JAY TDirectorAug 23Sale172.9920,0003,459,877488,061Aug 25 08:43 PM
EPSTEIN ROBERT SDirectorAug 22Sale170.2730051,0817,224Aug 24 07:52 PM
EPSTEIN ROBERT SDirectorAug 22Sale170.2730051,0817,224Aug 23 08:19 PM
BRADBURY DANIELDirectorAug 17Option Exercise71.0960042,65417,065Aug 18 08:31 PM
BRADBURY DANIELDirectorAug 17Sale168.42600101,05316,465Aug 18 08:31 PM
FLATLEY JAY TDirectorAug 15Option Exercise36.3010,000363,000498,061Aug 16 06:56 PM
FLATLEY JAY TDirectorAug 15Sale170.0010,0001,700,000488,061Aug 16 06:56 PM
WHITFIELD ROY ADirectorAug 12Option Exercise42.824,000171,2806,853Aug 15 06:03 PM
WHITFIELD ROY ADirectorAug 12Sale167.224,000668,8802,853Aug 15 06:03 PM
FLATLEY JAY TDirectorAug 09Option Exercise36.3010,000363,000498,061Aug 10 09:40 PM
FLATLEY JAY TDirectorAug 09Sale165.9710,0001,659,650488,061Aug 10 09:40 PM
Dadswell CharlesSr VP & General CounselAug 04Sale164.6311619,09740,132Aug 08 06:36 PM
FLATLEY JAY TDirectorAug 01Option Exercise36.3010,000363,000498,061Aug 02 07:27 PM
FLATLEY JAY TDirectorAug 01Sale170.0010,0001,700,000488,061Aug 02 07:27 PM
Dadswell CharlesSr VP & General CounselJul 27Sale155.008,6321,337,96040,248Jul 28 07:44 PM
FLATLEY JAY TDirectorJul 26Option Exercise36.3010,000363,000498,061Jul 28 07:39 PM
FLATLEY JAY TDirectorJul 26Sale150.0010,0001,500,000488,061Jul 28 07:39 PM
EPSTEIN ROBERT SDirectorJul 20Sale150.0030045,0007,524Jul 20 08:08 PM
FLATLEY JAY TDirectorJul 18Option Exercise36.3010,000363,000498,061Jul 20 08:06 PM
EPSTEIN ROBERT SDirectorJul 18Sale150.00900135,0007,824Jul 20 08:08 PM
FLATLEY JAY TDirectorJul 18Sale150.0010,0001,500,010488,061Jul 20 08:06 PM
BOWMAN A BLAINEDirectorJul 14Option Exercise42.825,000214,10020,704Jul 15 06:53 PM
BOWMAN A BLAINEDirectorJul 14Sale147.145,000735,70515,704Jul 15 06:53 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerJul 11Sale141.89716101,59318,976Jul 12 07:47 PM
BOWMAN A BLAINEDirectorJun 16Option Exercise42.825,000214,10020,704Jun 17 07:53 PM
BOWMAN A BLAINEDirectorJun 16Sale135.085,000675,38815,704Jun 17 07:53 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerJun 15Sale137.902,141295,24219,692Jun 15 06:47 PM
WHITFIELD ROY ADirectorJun 13Option Exercise42.822,00085,6406,653Jun 15 06:34 PM
WHITFIELD ROY ADirectorJun 13Sale140.443,800533,6722,853Jun 15 06:34 PM
EASTHAM KARINDirectorJun 01Option Exercise36.295,000181,45017,424Jun 03 07:28 PM
EASTHAM KARINDirectorJun 01Sale145.355,000726,75012,424Jun 03 07:28 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMay 25Sale144.732,141309,86721,833May 26 07:44 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMay 17Sale140.842,141301,53223,974May 19 06:56 PM
BOWMAN A BLAINEDirectorMay 12Option Exercise36.295,000181,45018,615May 13 06:03 PM
BOWMAN A BLAINEDirectorMay 12Sale137.115,000685,53513,615May 13 06:03 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 27Sale138.462,141296,44626,115Apr 28 06:34 PM